IMV:TSX; IMMVF:OTCQX

Immunovaccine Inc.

Immunovaccine Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Immunovaccine develops T cell-activating cancer immunotherapies and other vaccine candidates based on DepoVax™, the company's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell-activating therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing its lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The company is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus.
IMV:TSX IMMVF:OTCQX

Expert Comments:

André Uddin, Mackie Research Capital (12/7/17)
"Immunovaccine Inc. announced this morning that it was advancing DPX-NEO (a cancer vaccine) into a Phase 1 trial in conjunction with UConn Health. . .DPX-NEO should diversify the company's pipeline. . .we are maintaining our Speculative Buy rating and target price of $2.80."

This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts.
read more >
Douglas Loe, Echelon Wealth Partners (12/5/17)
"Immunovaccine Inc. presented more interim data from its 40-patient, Phase 1/2, recurrent ovarian cancer trial, testing its lead lipid (DepoVax)-based, water-free, survivin-containing cancer immune therapy DPX-Survivac in combination with partner Incyte's IDO1 checkpoint inhibitor, small-molecule drug epacadostat. . .[it's] still early days for DPX-Survivac Phase 1/2 oncology activities, but encouraging signals that the immune therapy works as expected in ovarian cancer are already available."

André Uddin, Mackie Research Capital (12/5/17)
"We are increasing our target price to $2.80 from $2.20 previously, as Immunovaccine Inc. reported good results of a Phase 1b study testing the combined treatment of the company's DPX-Surivivac and Incyte's IDO1 inhibitor epacadostat in advanced ovarian cancer patients. . .of the ten ovarian cancer patients who completed the treatment with DPX-Survivac plus 100 mg epacadostat, three had partial responses and four had stable diseases, yielding an impressive objective response rate of 30% and a disease control rate of 70%."

Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus.
read more >
André Uddin, Mackie Research Capital (11/21/17)
"Immunovaccines Inc. announced it is expanding its collaboration with Leidos to develop a DepoVax-based malaria vaccine candidate. We are maintaining our SPECULATIVE BUY rating and target price of $2.20. . .following the achievement of several preclinical milestones, Leidos and the U.S. Agency for International Development selected IMV's DepoVax platform as one of the preferred formulations to further develop a preventative, peptide-based malaria vaccine candidate. . .Leidos and USAID made this decision as IMV's DepoVax-formulated vaccine candidates demonstrated immune protection against the malaria parasite delivered by mosquito bites in prior studies."

Douglas Loe, Echelon Wealth Partners (11/21/17)
"Immunovaccine Inc. provided a pipeline update this morning, with yet another example of how its lipid-based, water-free DepoVax platform can engender antigen-specific B-cell and T-cell immune response, in this case in malaria in partnership with VA-based conglomerate Leidos. . .the key takeaway today is that the partnership generated sufficiently positive preclinical data to justify, in Leidos' view, advancing into formal clinical testing. We assume that Leidos will assume most clinical costs other than production of DepoVax, so forthcoming malaria clinical studies do not materially impact our near-term EBITDA or cash flow projections that remain more focused on DPX-Survivac and DPX-RSV."

Endri Leno, National Bank of Canada (11/10/17)
"Immunovaccine Inc. reported Q3 results that were in line with our estimate. . .the company also maintained its expectation/guidance that it sees the cash burn rate remain in the $2-3M range over the next 12 months. . .Immunovaccine offers not only a compelling portfolio of treatment candidates in the deal-focused immunotherapy space, but also a treatment delivery platform with significant applications in infectious diseases. The company has a series of, potentially de-risking, milestones/catalysts over the next 7-8 months as it will report results for two efficacy clinical trials in ovarian cancer, alongside partner drugs Keytruda and Epacadostat."

More Expert Comments

Experts Following This Company

Endri Leno, Equity Analyst – National Bank of Canada
Douglas Loe, Analyst – Echelon Wealth Partners
Jason McCarthy, Analyst – Maxim Group
André Uddin – Mackie Research Capital

The information provided above is from analysts, newsletters, the company and other contributors.

Immunovaccine Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Unique Delivery Platform
 
Unique target (survivin) in Immuno-Oncology for T Cell activation
 
Multiple clinical milestones between now and the end of 2018
catalyst Calendar